← All trials
NCT05743075
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2023
- Primary completion
- Nov 1, 2024
- Completion date
- Feb 1, 2025
- First posted
- Feb 24, 2023
- Last posted
- Mar 31, 2023
- Enrollment
- 488
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nuance BiotechLead sponsor
- LabCorpCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.